Basaglar Approval History
- FDA approved: Yes (First approved December 16th, 2015)
- Brand name: Basaglar
- Generic name: insulin glargine
- Dosage form: Injection
- Company: Eli Lilly and Company and Boehringer Ingelheim
- Treatment for: Diabetes, Type 1, Diabetes, Type 2
Basaglar (insulin glargine injection) is a long-acting human insulin analog indicated to improve glycemic control in patients with type 1 and type 2 diabetes mellitus.
Basaglar is similar to Lantus (insulin glargine injection) though it is not approved as a biosimilar product. Basaglar was approved through an abbreviated approval pathway that included data from two Basaglar-specific clinical trials, and additional evidence that demonstrated Basaglar was sufficiently similar to Lantus to justify its safety and effectiveness.
Basaglar is administered by subcutaneous injection once daily at the same time each day.
The most common side effects reported during clinical trials included hypoglycemia, allergic reactions, injection site reactions, pitting at the injection site, itching, rash, edema, and weight gain.
Development History and FDA Approval Process for Basaglar
|Dec 17, 2015||FDA Approves Basaglar (insulin glargine) for Type 1 and Type 2 Diabetes|
Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.